between energy and substrate intake and energy expenditure and substrate utilisation, any factor Background -Patients with chronic obstructive pulmonary disease (COPD) are which alters this balance may have detrimental effects. Using standard methods of indirect frequently malnourished and have increased resting energy expenditure (REE). calorimetry, previous studies have found an increased resting energy expenditure (REE) in An increase in the work of breathing is generally considered to be the main cause patients with COPD. [4] [5] [6] [7] [8] This has been attributed mainly to an increased cost of breathof this hypermetabolism, but other factors may also be implicated. Bronchodilators ing, 9 but several other factors have been suspected, 10 including drugs. 11 12 Inhaled antimay decrease the work of breathing by reducing airway obstruction, but 2 ad-cholinergic drugs are not known to induce a thermogenic effect, but in normal subjects oral renergic agents have a thermogenic effect. The aim of this study was to determine theophylline 13 and oral and inhaled 2 adrenergic drugs 11 14 increase REE. A similar therthe effect of salbutamol and ipratropium bromide administration on REE in mogenic effect can be expected in patients with chronic airflow limitation. On the other hand, patients with COPD. Methods -Thirteen patients (10 men) of bronchodilating drugs may decrease the work of breathing by reducing airway obstruction, mean (SD) age 68.3 (7.3) years and forced expiratory volume in one second (FEV 1 ) and thereby the REE. Thus, the net thermogenic effect of bronchodilators is unknown 39.0 (17.0)% predicted were studied on three consecutive days. The REE was in COPD and may differ according to the type of pharmacological agent. measured by indirect calorimetry at 30, 60, 120, and 180 minutes after double blind This study was undertaken to examine whether bronchodilators had a thermogenic nebulisation of either salbutamol, ipratropium bromide, or placebo in random effect in patients with stable COPD. To test this hypothesis we measured the effects on REE order. Results -FEV 1 increased both after sal-of three substances administered by nebulisation -a 2 adrenergic bronchodilator (salbutamol and after ipratropium. The difference in the mean response between butamol), an anticholinergic bronchodilator (ipratropium bromide), and placebo. salbutamol and placebo over 180 minutes was +199 ml (95% CI +104 to +295). The difference in mean response between ipratropium and placebo was +78 ml (95% Methods CI +2 to +160). REE increased after  salbutamol but was not changed after Thirteen patients with stable COPD were studipratropium. The difference in mean ied at the end of a stay in the Pulmonary 
weight range for height in the table of the     Heart rate was measured continuously during Metropolitan Life Insurance Company. 15 The body mass index (BMI) was calculated by di-the test by a portable device (Baumann Construction Electronique Médicale, Fleurier, viding the body weight (kg) by the height squared (m 2 ). Body fat content was estimated Switzerland) and the mean value was calculated in the last 10 minutes of each calorimetry by measuring skinfold thickness at four sitesbicipital, tricipital, subscapular, and supra-period. The respiratory rate was counted by the attending physician looking at the patient's iliac 16 17 -with a caliper (Lange Caliper, Cambridge Scientific Industries Inc, Cambridge, respiratory movements during three periods of two minutes in each calorimetry period. Massachusetts, USA). All measurements were made in triplicate by the same investigator. Fatfree mass (FFM) was calculated by subtracting the fat content from the body weight. The fat-  On the first day of the study the theophylline free mass was also assessed by bioelectrical impedance analysis by measuring the whole concentration was measured with a polarisation fluorescence system (TDx, Abott Laboratories, body resistance (Z-mètre, Division Autonome d'Electronique Médicale CHUV, Lausanne, North Chicago, Illinois, USA) in the serum of patients who were treated with xanthine Switzerland) to a low alternating current passing between the right wrist and the right ankle. 18 derivatives. Blood samples were taken in the morning at the predicted trough levels of theoThe impedance was measured in triplicate and the fat-free mass calculated using the equation phylline. of Schols et al. 19 
 
The study was performed in three sessions on three consecutive mornings after an overnight fast. For the six patients taking xanthine drugs    Forced expiratory flow rates were measured by the dose was unchanged for at least three days before the study and during the study. All a mass flow anemometer (SensorMedics 2200 Pulmonary Function Laboratory, Sensor-patients were requested to stop any oral 2 adrenergic drug or inhaled long acting 2 adMedics Corp, California, USA), and carbon monoxide transfer factor (T) by the single renergic drug 24 hours before the beginning of the study. They did not receive short acting 2 breath method (SensorMedics). Arterial blood gas tensions were measured by a blood gas adrenergic drugs for at least 10 hours before each measurement session. During each sesanalyser (AVL Blood Gas Analyser 995 S, AVL Medical AG, Schaffhausen, Switzerland). Dur-sion, after 20 minutes of rest, calorimetry measurements were carried out, the patients lying ing the experimental sessions forced expiratory flow rates were measured by a pneumo-supine with the head elevated at 30 degrees and placed in the hood. The patients were tachometer (Multispiro SA/100, Medical Equipment Design Inc, California, USA). Ref-asked to remain completely quiet. They did not watch television or listen to the radio during erence values were those proposed by Quanjer et al. 20 the measurements. The investigators ensured that the patients did not move or sleep. After initiating calorimetry, time was allowed for energy expenditure (EE) to stabilise, which usually occurred within 15 minutes. The EE was measured until at least 15 minutes of steady   REE was measured by indirect calorimetry with state were obtained to determine the REE.
After these initial measurements the patients a transparent ventilated hood placed over the head of the patient. A constant fraction of the received a different treatment in each session in random order, consisting of either 5 mg air flowing through the hood was collected for analysis in an indirect calorimetry device salbutamol, 0.5 mg ipratropium bromide, or placebo (NaCl 0.9%), administered by wet (Deltatrac, Datex Instrumentarium Corp., Helsinki, Finland). Oxygen concentration was nebulisation (inhalation device Pari-Master with Pari-LC Plus atomizer, Pari-Werk GmbH, measured by a paramagnetic oxygen sensor and carbon dioxide concentration by an infrared Starnberg, Germany). The doses of salbutamol and ipratropium were chosen after a review of sensor. The energy expenditure (EE) was calculated from these values according to the the literature [22] [23] [24] which suggested that they were equipotent in terms of bronchodilation. method of Bursztein et al. 21 The calorimetric measurements were continuously integrated The randomisation was made in blocks of six patients since there were six possible orders of over consecutive one minute intervals. The accuracy and precision of the calorimeter were administration of the three treatments. The solutions were prepared by a member of staff assessed by an infusion test using nitrogen and carbon dioxide over a period of one hour and not involved in the protocol who randomly chose one of the six possible orders of ad-48 minutes. The mean (SD) measured oxygen consumption was 100.6 (1.7)% of the actual ministration and prepared 2 ml of solution for nebulisation containing either salbutamol, ipvalue and measured carbon dioxide production was 101.3 (1.4)% of the actual value. The ratropium, or placebo in three different test tubes labelled 1, 2, and 3 for the three days of device was calibrated immediately before each measurement with a reference gas mixture.
the test.
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The time at the end of nebulisation was taken were allowed to sit on a chair next to the bed, but without exerting themselves. They did not receive any other medication or food during Each day the change in REE after the treatment
All measures made at 400 m above sea level.
was expressed as a percentage of the baseline value measured on the same day.
  
The mean FEV 1 was 39% predicted (range 24-76). Seven patients were emphysematous   on the basis of a T of <60% of predicted The mean baseline REE values during the values. Four patients were hypoxaemic (Pa 2 three measurement sessions were compared by Ζ8 kPa or 60 mmHg) and three were hyperrepeated measures ANOVA. Post-tests were capnic (Pa 2 [6 kPa or 45 mmHg) (table 2) . then performed with a Bonferroni t test as The effects of the treatments on FEV 1 are described by Glantz. 26 For each parameter shown in fig 1. Measurements could not be (FEV 1 , REE, heart rate, respiratory rate) the obtained in one patient because of intense effect of each treatment (salbutamol, ipra-coughing during each forced expiratory mantropium, placebo) was assessed by calculating oeuvre. The difference in mean response befor each subject the area under the curve which tween salbutamol and placebo was +199 ml can be interpreted as the cumulative response (95% CI +104 to +295; p<0.001). The to treatment. 27 The area under the curve was difference in mean response between ipradivided by the duration of the study (180 min-tropium and placebo was +78 ml (95% CI utes) to obtain the mean response as the sum-+2 to +160; p<0.05). As expected, the time mary measure. Differences between treatments course of bronchodilation was different with were then compared using repeated measures the two drugs, the maximum increase in FEV 1 ANOVA, followed by paired t tests to compare occurring 60 minutes after nebulisation of salsalbutamol and ipratropium with placebo. The butamol and 180 minutes after nebulisation of relationship between the maximal change in ipratropium. REE after bronchodilator and the baseline REE was analysed by linear regression. The baseline REE was compared between patients receiving theophylline and those not receiving theophylline by a two-tailed unpaired t test. The increase in REE 60 minutes after salbutamol in patients receiving theophylline was compared with the increase measured in patients who did not receive theophylline by a two-tailed unpaired t test. Significance was determined at the 5% level. All reported values are means (SD).
Results

 
Two patients were obese (body weight 148.5% and 158.0% of IBW) and two were underweight (85.6% and 89.0% of IBW). The mean weight 1).
group 100.3 (5.8)% predicted in patients receiving theophylline and 100.0 (4.1)% in those not   Before nebulisation the mean REE of the three receiving theophylline (p>0.9). There was no difference in maximal REE after salbutamol sessions was 1456 (260) kcal/24 hours which represented 100.2 (4.9)% of the predicted between the patients who received theophylline and those who did not. value or 25.3 (1.9) kcal/24 hours/kg of FFM measured by bioelectrical impedance (fig 2) . There was no difference between the baseline REE on placebo (1460 (265) kcal/24 hours), Discussion Theoretically, bronchodilators could have two ipratropium (1453 (257) kcal/24 hours), or salbutamol (1456 (266) kcal/24 hours). How-opposite effects on REE in patients with airway obstruction -firstly an increase in REE due to ever, the baseline REE was 3.5% higher in the first measurement session than in the last a direct thermogenic effect 28 and secondly a decrease in REE due to diminished work of (p<0.01).
REE increased after salbutamol but there was breathing because of bronchodilation. Our results are consistent with a thermogenic no change after ipratropium. The difference in the mean response between salbutamol and effect of 2 adrenergic drugs. Compared with placebo, we found a maximal 7.3% increase placebo was +4.8% of baseline REE (95% CI +2.2 to +7.4 %; p<0.002). The difference in in REE 30 minutes after the nebulisation of salbutamol (fig 2) which was sustained with a the mean response between ipratropium and placebo was −0.4% of the baseline REE (95% mean increase of 4.8% over the 180 minutes of the measurement sessions. The thermogenic CI −2.3 to +1.5%; NS). effect of sympathetic nervous system stimulation has long been recognised and is mediated by both 1 and 2 receptors. 28 The agonists     The mean heart rate before nebulisation was used as bronchodilators are all 2 selective and all have similar metabolic effects. Oral ter-74.5 (14.9) beats/minute. This increased after salbutamol but no change occurred after ip-butaline administered in a dose of 15 mg per day for two weeks in normal subjects increased ratropium (fig 3) . The difference in the mean response between salbutamol and placebo was energy expenditure by 7.7%, 14 and 5 mg of salbutamol administered by wet nebulisation +5.5 beats/min (95% CI +2.6 to +8.4; p<0.002). The difference in the mean response increased REE by 8.2% in patients with cystic fibrosis. 29 The increase in REE after inhaled between ipratropium and placebo was −1.5 beats/min (95% CI −3.1 to 0.1; NS). Neither salbutamol has recently been found to be dosedependent in normal subjects. 11 Our results salbutamol nor ipratropium had any effect on respiratory rate. The difference in the mean suggest that the effect of salbutamol in patients with COPD is similar to the effect described response between salbutamol and placebo was −0.1 breaths/min (95% CI −1.4 to +1.1; in normal subjects and patients with cystic fibrosis. However, it is difficult to compare the NS). The difference in the mean response between ipratropium and placebo was 0.0 magnitude of the increase in REE because of the different drugs, doses, and modes of breaths/min (95% CI −0.7 to +0.8; NS). administration used in these studies. Drug tolerance has not been found with the chronic use of ipratropium, 30 but it develops   The mean serum level of the six patients re-with chronic use of agonists. 31 All our patients were treated with salbutamol on a regular basis. ceiving theophylline was 50.2 (15.1) mmol/l (therapeutic range 45-110 mmol/l). This was For ethical reasons and in order to study these patients in their usual clinical condition, this not correlated with baseline REE which was group.bmj.com on April 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from treatment was continued except for 10 hours REE of our patients was not increased. In some studies 4-8 patients had received bronchodilators before and during the measurement sessions. Despite this regular 2 adrenergic treatment we before the measurement of REE, possibly leading to an overestimation of true basal metawere able to measure an increase in REE after salbutamol. This is in agreement with the study bolism. In addition, the reported baseline REE of our patients was calculated as the mean of cited above 14 in which an increase in REE in response to an infusion of isoprenaline was still the three sessions. REE was 3.5% higher in the first measurement session than in the last. present, although blunted, after two weeks of treatment with terbutaline. In patients with Taking values from a single measurement session could therefore lead to a slight overcystic fibrosis 29 nebulisation of salbutamol also increased REE in the subgroup chronically estimate of the REE. Finally, there is no evidence that the effects of the bronchodilators treated with 2 agonists, but to a lesser extent than in those not receiving 2 agonists. This on REE would have been different with a higher baseline REE. In our patients there was no contrasts with a study in normal subjects in which treatment with salbutamol for 13 days correlation between the baseline REE and the maximal increase in REE after salbutamol. prevented an acute thermogenic effect occurring after inhalation of the drug. 32 Because Furthermore, the baseline REE values during the measurement sessions with salbutamol, a certain degree of drug tolerance was likely to be present in our patients, the increase in REE ipratropium, or placebo were the same.
The increase in REE measured in patients measured after salbutamol could be expected to have been larger if they had not been receiving with COPD is particularly relevant in underweight patients because it has been cited as regular treatment with 2 agonists or if we had interrupted this treatment earlier.
the main cause of their malnutrition. 10 The mean weight of our patients was normal, but The relative increase in heart rate and in REE followed a similar time course (peak at among them were two patients who were obese and two who were underweight. The effects of 30 minutes) but was of a different magnitude (figs 2 and 3). This could be explained by two the bronchodilators on FEV 1 , REE, and heart rate were similar in the obese subgroup, the distinct effects of salbutamol -a chronotropic effect mediated by receptors of the heart and underweight subgroup, and in the remaining patients (data not shown). This suggests that a thermogenic effect whose mechanism is not fully elucidated but which is likely to be related the thermogenic effect of salbutamol is independent of nutritional status, although the to skeletal muscle. 11 The measured increase in heart rate is probably not clinically relevant, small number of patients in each group does not allow one to draw definite conclusions. but it confirms a metabolic effect of salbutamol by a method independent of calorimetry. The
Are our results clinically relevant? The increase in REE after the nebulisation of 5 mg fact that the heart rate increased despite chronic treatment with 2 agonists argues against a salbutamol was maximal at 30 minutes but was sustained with a mean change of 4.8% over dissociation between the downregulation of the thermogenic and cardiac effects of the drug. 32 180 minutes. Assuming that the patients take this high dose every six hours and that the In contrast, ipratropium bromide has no thermogenic effect and, as expected, we found mean increase in REE over this period is 3%, this excess in energy expenditure would repno increase in energy expenditure after ipratropium. resent about 16 000 kcal over a year, or the energy equivalent of 1.8 kg of fat. It should be We chose the doses of salbutamol and ipratropium according to the literature. In the noted, however, that the increase in REE due to bronchodilator treatment could be comthree studies comparing the wet nebulisation of these drugs in COPD [22] [23] [24] the degree of pensated by changes in other factors contributing to the total energy balance such as a bronchodilation produced by 5 mg of salbutamol or 0.5 mg of ipratropium was equi-decrease in activity induced energy expenditure or an increase in food intake. As the thermovalent. In our study both drugs induced bronchodilation but with a different time genic effect of salbutamol is dose-dependent, 11 a smaller dose would induce a lesser increase course (fig 1) . This is not surprising since the pharmacokinetic properties of the two drugs in REE. In addition, it is difficult to compare the dose delivered by wet nebulisation with differ. In view of the total absence of a thermogenic effect of ipratropium the different time that by other methods of administration such as metered dose inhalers. course of bronchodilation is not likely to affect our results.
In conclusion, the nebulisation of salbutamol, but not ipratropium bromide, inTheophylline causes an increase in REE in normal subjects. 13 The dose of theophylline duced a sustained increase in the REE of patients with COPD treated with bronchoprescribed was unchanged three days before the study and during the study and we assumed dilators on a chronic basis. The observed thermogenic effect of 2 agonists does not explain that the plasma level of the drug was stable. Besides, theophylline does not modify the acute the hypermetabolism frequently present in COPD because hypermetabolism has also been thermogenic response to inhaled salbutamol. 13 No difference was found in the baseline REE reported after withdrawal of 2 agonists. However, when added to other factors, it may further or in the maximal increase in REE after salbutamol between the patients who received disrupt the energy balance. theophylline and those who did not.
REE is often higher than predicted in patients 
